Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
2.437
-0.063 (-2.52%)
Aug 14, 2025, 10:57 AM - Market open
Company Description
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Armata Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Deborah Birx |
Contact Details
Address: 5005 McConnell Avenue Los Angeles, California 90066 United States | |
| Phone | 310 665 2928 |
| Website | armatapharma.com |
Stock Details
| Ticker Symbol | ARMP |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921114 |
| CUSIP Number | 04216R102 |
| ISIN Number | US04216R1023 |
| Employer ID | 91-1549568 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Deborah L. Birx M.D. | Chief Executive Officer and Director |
| David D. House | Senior Vice President of Finance and Principal Financial Officer |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
| Peter Hubbard | Vice President of Operations |
| Bani Tchekanova Ph.D. | Head of Regulatory Strategy and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 13, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 12, 2025 | SCHEDULE 13D/A | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 1, 2025 | 8-K | Current Report |